G49N Stock Overview A clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. More details
Rewards Risk Analysis + 4 more risks
See All Risk Checks Capture your thoughts, links and company narrative
GenSight Biologics S.A. Competitors Price History & Performance
Summary of share price highs, lows and changes for GenSight Biologics Historical stock prices Current Share Price €0.23 52 Week High €0.49 52 Week Low €0.23 Beta 2.15 1 Month Change -20.61% 3 Month Change -28.46% 1 Year Change -50.21% 3 Year Change -95.74% 5 Year Change -92.71% Change since IPO -97.15%
Recent News & Updates
GenSight Biologics Announces Submission of LUMEVOQ Dossier to ANSM to Prepare for Restart of Early Access Program in France Nov 13
First half 2024 earnings released: €0.071 loss per share (vs €0.26 loss in 1H 2023) Sep 30
New major risk - Financial position Sep 27
GenSight Biologics S.A. Provides Business Update Jul 23 Gensight Biologics S.A. Appoints William Monteith to Its Board of Directors
New major risk - Shareholder dilution Apr 24 See more updates
GenSight Biologics Announces Submission of LUMEVOQ Dossier to ANSM to Prepare for Restart of Early Access Program in France Nov 13
First half 2024 earnings released: €0.071 loss per share (vs €0.26 loss in 1H 2023) Sep 30
New major risk - Financial position Sep 27
GenSight Biologics S.A. Provides Business Update Jul 23 Gensight Biologics S.A. Appoints William Monteith to Its Board of Directors
New major risk - Shareholder dilution Apr 24
Full year 2023 earnings released: €0.54 loss per share (vs €0.60 loss in FY 2022) Apr 22 GenSight Biologics S.A. to Report Q3, 2024 Results on Oct 24, 2024
New major risk - Revenue and earnings growth Mar 12
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024 Mar 12
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024 Mar 06
New major risk - Shareholder dilution Feb 19 GenSight Biologics S.A. has completed a Follow-on Equity Offering in the amount of €5 million. Feb 08
Gensight Biologics S.A. Announces CFO Changes Jan 26
New minor risk - Shareholder dilution Jan 20
GenSight Biologics Announces Board Changes Jan 17 GenSight Biologics S.A. Announces CEO Changes Dec 22
Gensight Biologics S.A. Confirms Second Successful GMP Batch of Lumevoq Nov 17
GenSight Biologics S.A. Announces Preliminary Assay Indicating Successful Manufacture of Second LUMEVOQ® GMP Batch Nov 14
GenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ Sep 27
GenSight Biologics Announces Successful Manufacture of LUMEVOQ GMP Batch Sep 18
First half 2023 earnings released: €0.26 loss per share (vs €0.23 loss in 1H 2022) Sep 18
No longer forecast to breakeven May 25
No longer forecast to breakeven Apr 23
Forecast to breakeven in 2025 Apr 06
Full year 2022 earnings released: €0.60 loss per share (vs €0.63 loss in FY 2021) Mar 27
Forecast to breakeven in 2024 Mar 24
GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals Feb 13 GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy Dec 15
GenSight Biologics Announces Publication of Results of LUMEVOQ® REFLECT Pivotal Clinical Trial in Peer-Reviewed Journals Nov 17
Insufficient new directors Nov 16
GenSight Biologics S.A Announces Successful Completion of LUMEVOQ Engineering Batch Validating Implemented Corrective Actions Sep 19
GenSight Biologics Appoints Philippe Motté as Senior Vice President, Regulatory and Quality Sep 12
Insufficient new directors Aug 01
First half 2022 earnings released Jul 29
Insufficient new directors Jul 02
GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology May 19
GenSight Biologics Grants Six-Month Extension in LUMEVOQ® European Regulatory Review Apr 14
Full year 2021 earnings released: €0.63 loss per share (vs €0.97 loss in FY 2020) Apr 11 GenSight Biologics S.A. Provides Update on LUMEVOQ® Manufacturing Timeline
Gensight Biologics to Present Reflect Phase III Data with LUMEVOQ® At the NANOS 2022 Meeting Feb 15
GenSight Biologics Appoints Sissel Rodahl as Senior Vice-President of Commercial Operations to Lead the Launch of Lumevoq® in Europe Feb 01
GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy Jan 24
Forecast to breakeven in 2024 Jan 01
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection Dec 01
GenSight Biologics S.A. Announces Positive Data Safety Monitoring Board Review of Pioneer Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa Sep 16
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials Sep 10
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ Sep 02
First half 2021 earnings released: €0.19 loss per share (vs €0.43 loss in 1H 2020) Aug 02
GenSight Biologics S.A. Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use in France Jul 06
Gensight Biologics Reports Topline Results from Reflect Phase III Clinical Trial, Confirming Lumevoq® Efficacy Including Better Efficacy with Bilateral Treatment Jun 30
GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ versus Natural History in Frontiers in Neurology Jun 01
GenSight Biologics S.A. Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye May 04
Full year 2020 earnings released: €0.97 loss per share (vs €1.09 loss in FY 2019) Apr 12
Full year 2020 earnings released: €0.97 loss per share (vs €1.08 loss in FY 2019) Mar 12
Revenue misses expectations Mar 12
New 90-day high: €9.25 Feb 25
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs Feb 16
GenSight Biologics Submittes to the ANSM an Application for A Cohort ATU Jan 20 GenSight Biologics S.A. to Report Fiscal Year 2020 Results on Mar 10, 2021
New 90-day high: €7.76 Jan 13
GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine Dec 11
New 90-day high: €6.01 Nov 26
GenSight Biologics Reports Validation of LUMEVOQ Marketing Authorisation Application by European Medicines Agency Nov 05
First half earnings released Oct 25
GenSight Biologics S.A. Provides Operational Update Oct 15
GenSight Biologics Appoints Elsy Boglioli to Its Board of Directors Oct 14
New 90-day high: €3.31 Sep 25
GenSight Biologics Reports New Analysis Demonstrating Statistically Significant and Clinically Meaningful Difference Between Visual Outcomes in LUMEVOQ®-Treated Patients Sep 21
New 90-day low - €2.88 Aug 27 Shareholder Returns G49N DE Biotechs DE Market 7D 1.7% 2.5% -0.4% 1Y -50.2% -10.2% 7.9%
See full shareholder returns
Return vs Market: G49N underperformed the German Market which returned 7.9% over the past year.
Price Volatility Is G49N's price volatile compared to industry and market? G49N volatility G49N Average Weekly Movement 19.2% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: G49N's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: G49N's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.
Show more GenSight Biologics S.A. Fundamentals Summary How do GenSight Biologics's earnings and revenue compare to its market cap? G49N fundamental statistics Market cap €31.15m Earnings (TTM ) -€20.11m Revenue (TTM ) €1.98m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) G49N income statement (TTM ) Revenue €1.98m Cost of Revenue €0 Gross Profit €1.98m Other Expenses €22.08m Earnings -€20.11m
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Jan 23, 2025
Earnings per share (EPS) -0.17 Gross Margin 100.00% Net Profit Margin -1,017.51% Debt/Equity Ratio -85.5%
How did G49N perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 11:15 End of Day Share Price 2025/01/03 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources GenSight Biologics S.A. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ingrid Gafanhão Bryan Garnier & Co Gbolahan Amusa Benz Chardan Capital Markets, LLC Daniil Gataulin Chardan Capital Markets, LLC
Show 3 more analysts 
